Literature DB >> 22889974

Targeted therapies: Cetuximab dosing by rash--is the scaling of EVEREST meaningful?

Sebastian Stintzing, Heinz-Josef Lenz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22889974     DOI： 10.1038/nrclinonc.2012.142

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

Authors:  D M Shin; N J Donato; R Perez-Soler; H J Shin; J Y Wu; P Zhang; K Lawhorn; F R Khuri; B S Glisson; J Myers; G Clayman; D Pfister; J Falcey; H Waksal; J Mendelsohn; W K Hong
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

Authors:  Heinz-Josef Lenz; Eric Van Cutsem; Shirin Khambata-Ford; Robert J Mayer; Philip Gold; Philip Stella; Barry Mirtsching; Allen L Cohn; Andrew W Pippas; Nozar Azarnia; Zenta Tsuchihashi; David J Mauro; Eric K Rowinsky
Journal:  J Clin Oncol       Date:  2006-10-20       Impact factor: 44.544

3.  Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.

Authors:  Eric Van Cutsem; Sabine Tejpar; Dirk Vanbeckevoort; Marc Peeters; Yves Humblet; Hans Gelderblom; Jan B Vermorken; Frederic Viret; Bengt Glimelius; Elisa Gallerani; Alain Hendlisz; Annemieke Cats; Markus Moehler; Xavier Sagaert; Soetkin Vlassak; Michael Schlichting; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

4.  A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.

Authors:  Paula M Fracasso; Howard Burris; Matthew A Arquette; Ramaswamy Govindan; Feng Gao; Lisa P Wright; Sherry A Goodner; F Anthony Greco; Suzanne F Jones; Noel Willcut; Catherine Chodkiewicz; Amit Pathak; Gregory M Springett; George R Simon; Daniel M Sullivan; Raphaël Marcelpoil; Shelley D Mayfield; David Mauro; Christopher R Garrett
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

5.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

6.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

7.  EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo.

Authors:  Francesca Mascia; Christophe Cataisson; Tang-Cheng Lee; David Threadgill; Valentina Mariani; Paolo Amerio; Chinmayi Chandrasekhara; Gema Souto Adeva; Giampiero Girolomoni; Stuart H Yuspa; Saveria Pastore
Journal:  J Invest Dermatol       Date:  2009-11-05       Impact factor: 8.551

8.  Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

Authors:  Josep Tabernero; Andres Cervantes; Fernando Rivera; Erika Martinelli; Federico Rojo; Anja von Heydebreck; Teresa Macarulla; Edith Rodriguez-Braun; Maria Eugenia Vega-Villegas; Stefanie Senger; Francisco Javier Ramos; Susana Roselló; Ilhan Celik; Christopher Stroh; José Baselga; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

9.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors:  Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.